Search Result

Results for "

Ovarian and Breast cancer.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) ADC Payload (9) Akt (2) Antibiotic (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (20) Aryl Hydrocarbon Receptor (1) Aurora Kinase (1) Biochemical Assay Reagents (1) Calcium Channel (1) Carbonic Anhydrase (1) Caspase (1) CDK (4) Checkpoint Kinase (Chk) (2) COX (1) Cytochrome P450 (8) Deubiquitinase (1) DNA/RNA Synthesis (5) Drug Derivative (1) Drug Intermediate (4) Drug Metabolite (2) Drug-Linker Conjugates for ADC (4) EGFR (2) Endogenous Metabolite (1) Ephrin Receptor (1) Estrogen Receptor/ERR (3) Ferroptosis (1) FLT3 (1) Folate Receptor (FR) (1) Fungal (3) GnRH Receptor (5) HDAC (1) Histone Methyltransferase (2) HMG-CoA Reductase (HMGCR) (1) Influenza Virus (3) Interleukin Related (1) Isotope-Labeled Compounds (10) JNK (1) Kinesin (1) Lipoxygenase (1) MAGL (1) MicroRNA (3) Microtubule/Tubulin (3) Mitochondrial Metabolism (1) Mitosis (1) Mucin (1) Na+/K+ ATPase (1) p38 MAPK (1) PARP (5) Peptide-Drug Conjugates (PDCs) (2) Phosphatase (2) Phospholipase (1) PI3K (1) Polo-like Kinase (PLK) (1) Potassium Channel (1) PROTACs (3) Proteasome (1) RAD51 (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (3) Sodium Channel (1) STAT (1) TAM Receptor (1) TMV (1) Topoisomerase (6) Transferrin Receptor (1) Transmembrane Glycoprotein (1) TROP2 (1) TRP Channel (1) VEGFR (1) Wee1 (1) Wnt (1)
By Research Areas:	Cancer (92) Endocrinology (13) Infection (3) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (5)

By Targets:

ADC Antibody (2)

ADC Payload (9)

Akt (2)

Antibiotic (3)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (20)

Aryl Hydrocarbon Receptor (1)

Aurora Kinase (1)

Biochemical Assay Reagents (1)

Calcium Channel (1)

Carbonic Anhydrase (1)

Caspase (1)

CDK (4)

Checkpoint Kinase (Chk) (2)

COX (1)

Cytochrome P450 (8)

Deubiquitinase (1)

DNA/RNA Synthesis (5)

Drug Derivative (1)

Drug Intermediate (4)

Drug Metabolite (2)

Drug-Linker Conjugates for ADC (4)

EGFR (2)

Endogenous Metabolite (1)

Ephrin Receptor (1)

Estrogen Receptor/ERR (3)

Ferroptosis (1)

FLT3 (1)

Folate Receptor (FR) (1)

Fungal (3)

GnRH Receptor (5)

HDAC (1)

Histone Methyltransferase (2)

HMG-CoA Reductase (HMGCR) (1)

Influenza Virus (3)

Interleukin Related (1)

Isotope-Labeled Compounds (10)

JNK (1)

Kinesin (1)

Lipoxygenase (1)

MAGL (1)

MicroRNA (3)

Microtubule/Tubulin (3)

Mitochondrial Metabolism (1)

Mitosis (1)

Mucin (1)

Na+/K+ ATPase (1)

p38 MAPK (1)

PARP (5)

Peptide-Drug Conjugates (PDCs) (2)

Phosphatase (2)

Phospholipase (1)

PI3K (1)

Polo-like Kinase (PLK) (1)

Potassium Channel (1)

PROTACs (3)

Proteasome (1)

RAD51 (1)

Ras (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (3)

Sodium Channel (1)

STAT (1)

TAM Receptor (1)

TMV (1)

Topoisomerase (6)

Transferrin Receptor (1)

Transmembrane Glycoprotein (1)

TROP2 (1)

TRP Channel (1)

VEGFR (1)

Wee1 (1)

Wnt (1)

By Research Areas:

Cancer (92)

Endocrinology (13)

Infection (3)

Inflammation/Immunology (2)

Metabolic Disease (1)

Neurological Disease (5)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

Epothilone F	Microtubule/Tubulin	Cancer
Epothilone F is a Microtubule/Tubulin-stabilizing agent with anti-tumor activity. Epothilone F inhibits the proliferation of breast cancer cells, non-small cell lung cancer cells, drug-resistant ovarian cancer cells .

Calycosin 10+ Cited Publications Cyclosin	Apoptosis	Neurological Disease Cancer
Calycosin is a compound that can be isolated from Radix Astragali. Calycosin has strong antioxidant, anti-inflammatory and apoptosis-modulating effects. Calycosin can be used for the research of ovarian cancer and breast cancer .

Cytembena	DNA/RNA Synthesis	Cancer
Cytembena is inhibitor for replicative DNA synthesis, purine synthesis and tetrahydrofolate formylase activity. Cytembena ameliorates ovarian or breast cancer, relieves the pain from skeletal metastases .

PROTAC PARP1 degrader-4	PROTACs PARP	Cancer
PROTAC PARP1 degrader-4 (Compound 180055) is a selective PARP1 PROTAC degrader (DC₅₀ in T47D and MDA-MB-231 cell lines is 180 nM and 240 nM, respectively). PROTAC PARP1 degrader-4 promotes ubiquitination and degradation of PARP1 as well as inhibits PARP1 enzyme activity without a noticeable DNA trapping effect. PROTAC PARP1 degrader-4 inhibits tumors carrying BRCA mutations with a minor impact on the growth of normal cells (Pink: PARP1 ligand (HY-10617A); Blue: E3 ligase VHL ligand (HY-125845); Black: linker (HY-W014787)) .

SMP-33693	Drug-Linker Conjugates for ADC	Cancer
SMP-33693 is a Drug-Linker Conjugate for ADC with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

SMP-93566	Drug-Linker Conjugates for ADC	Cancer
SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

BO-0742	Drug Derivative	Cancer
BO-0742, a derivative of AHMA and N-mustard, is a potent anti-cancer agent. BO-0742 significantly suppresses the growth of xenografts of human breast and ovarian cancers in mice .

SMP-88480	Drug-Linker Conjugates for ADC	Cancer
SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .

BHPI	Estrogen Receptor/ERR Phospholipase	Cancer
BHPI is a nuclear receptor ERα inhibitor. BHPI activates PLCγ and UPR. BHPI has antitumor activity against breast, endometrial, and ovarian cancers .

FC11409B	Carbonic Anhydrase	Cancer
FC11409B is an ureido-sulfamate carbonic anhydrase IX (CAIX) inhibitor. FC11409B inhibits proliferation and migration of breast cancer cell lines in both hypoxic (0.5% O₂) and normoxic conditions (21% O₂). FC11409B also inhibits 3D spheroid of breast cancer subtypes invasion. FC11409B is promising for research of breast and ovarian cancers .

PGE-M tetranor-PGEM	Endogenous Metabolite	Inflammation/Immunology Cancer
PGE-M is a metabolite of prostaglandin E₂ (PEG₂) as a biomarker of inflammation and cancer including advanced colorectal neoplasia, ovarian cancer, prostate cancer and so on. Urinary PGE-M is positively associated with obesity, smoking and lung metastases with breast cancer .

Verubulin MPC 6827	Microtubule/Tubulin	Cancer
Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research .

Wnt pathway inhibitor 5	Wnt	Cancer
Wnt pathway inhibitor 5 (Compound 28) is wnt pathway inhibitor, with an IC₅₀ value of < 0.003 μΜ. Wnt pathway inhibitor 5 inhibits many cancers, including ovarian teratocarcinoma cancer, breast cancer, osteosarcoma, head and neck squamous carcinoma .

Varsetatug CX-2051 antibody	Transmembrane Glycoprotein	Cancer
Varsetatug is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug has an antitumor activity. Varsetatug can be used for cancers such as breast, prostate and ovarian cancer research .

Onvitrelin ucalontide Phor18-LHRH (338613); EP-100	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

CHK1-IN-13	Checkpoint Kinase (Chk)	Cancer
CHK1-IN-13 (Compound 38) is a checkpoint kinase 1 (Chk1) inhibitor with an IC₅₀ of 10-50  nM. CHK1-IN-13 has anticancer activity, and can be used for the research of cancers, such as breast, ovarian and prostate cancer .

FiVe1	Proteasome Mitosis	Cancer
FiVe1 is a vimentin (VIM) inhibitor. FiVe1 binds to the rod domain of VIM, causing metaphase VIM disassembly and hyperphosphorylation at Ser56, ultimately leading to mitotic catastrophe, multinucleation, and loss of stemness. FiVe1 has anticancer activity against soft tissue sarcomas. FiVe1 increases the sensitivity of ovarian cancer to Cisplatin (HY-17394). FiVe1 can be used for researches of mesenchymal cancers (including breast cancer and soft tissue sarcoma) and ovarian cancers .

PARP1-IN-39	PARP	Cancer
PARP1-IN-39 is an inhibitor of PARP1 with an IC₅₀ of 0.22 nM. PARP1-IN-39 has an IC₅₀ of 1.57 nM in human breast cancer cells. PARP1-IN-39 can be studied in breast, ovarian, pancreatic, and prostate cancers associated with DNA repair deficiencies, such as BRCA1/2 mutations .

Apomine SR-45023A; SR 9223i; SK&F-99085	HMG-CoA Reductase (HMGCR) Apoptosis	Cancer
Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .

Estrogen receptor antagonist 7	Estrogen Receptor/ERR	Cancer
Estrogen receptor antagonist 7 (compound 13) is a potent estrogen receptors (ER) antagonist. Estrogen receptor antagonist 7 has antiproliferative activity against breast and ovarian cancer cells. Anticancer and anti-uterotrophic activities .

Glyceollin I	Estrogen Receptor/ERR	Metabolic Disease Cancer
Glyceollin I is a selective estrogen receptor (ER) modulator with anticancer, antioxidant, and anti-inflammatory activities. Glyceollin I is promising for research of estrogen-related cancers (e.g., breast, ovarian) and metabolic disorders (e.g., hypercholesterolemia) .

Calycosin (Standard) Cyclosin (Standard)	Reference Standards Apoptosis	Neurological Disease Cancer
Calycosin (Standard) is the analytical standard of Calycosin. This product is intended for research and analytical applications. Calycosin is a compound that can be isolated from Radix Astragali. Calycosin has strong antioxidant, anti-inflammatory and apoptosis-modulating effects. Calycosin can be used for the research of ovarian cancer and breast cancer .

CTM01 7F11C7	Mucin	Cancer
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .

Exemestane 5 Publications Verification FCE 24304; EXE	Cytochrome P450	Endocrinology Cancer
Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and *rat ovarian* aromatase*, respectively. Exemestane can be used for hormone-dependent breast* cancer research .

CDK2 degrader 8	CDK	Cancer
CDK2 degrader 8 (Compound1) is a CDK2 degrader. CDK2 degrader 8 shows potential anti-tumor activity by targeting CDK2. CDK2 degrader 8 can be used for the study of solid tumors (breast cancer, triple negative breast cancer, ovarian serous cystadenocarcinoma) and liquid tumors (diffuse large B-cell lymphoma, acute myelogenous leukemia) associated with abnormal CDK2 function .

Anti-BRCA1 Antibody (BR64)	DNA/RNA Synthesis	Cancer
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1 κ chimeric antibody, targeting to human BRCA1. Anti-BRCA1 Antibody (BR64) reacts with BRCA1 (Breast cancer susceptibility gene 1) involved in tumor suppression, transcription, genomic stability, DNA repair and recombination. Anti-BRCA1 Antibody (BR64) can be used for the detections of immunofluorescence, western blot, and immunoprecipitation in cancer, such as breast and ovarian cancer .

AB-3A4	ADC Antibody	Cancer
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Rotenolone	Others	Cancer
Rotenolone is an antiproliferative agent. Rotenolone shows antiproliferative activity against the ovarian cancer A2780, breast cancer BT-549, prostate cancer DU 145, NSCLC NCI-H460, and colon cancer HCC-2998 cell lines, with IC₅₀s of 0.95, 1.6, 2.7, 2.0, and 2.9 μM, respectively .

PLK1-IN-11	Polo-like Kinase (PLK)	Cancer
PLK1-IN-11 (Cluster 4, 16953209) is a PLK1 inhibitor, with IC₅₀ of 1 μM. PLK1-IN-11 can be used in research on a variety of cancers, including pancreatic, ovarian, breast, and non-small cell lung carcinoma .

And1-IN-1	DNA/RNA Synthesis	Cancer
And1-IN-1 is a potent And1 inhibitor with an IC₅₀ of 2.08 μM. And1-IN-1 binds to the N-terminus of And-1 and induces a conformational change in And-1, which promotes the interaction of And-1 with E3 ligase CUL4B for ubiquitin-mediated degradation. And1-IN-1 suppresses the growth of a broad range of cancers and resensitizes platinum-resistant ovarian cancer cells to platinum agents. And1-IN-1 can be used for the studies of ovarian cancer and breast cancer .

MAGL-IN-1	MAGL	Cancer
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC₅₀ of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .

Exatecan Intermediate 2	ADC Payload Drug Intermediate	Cancer
Exatecan Intermediate 2 (Compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

Exatecan Intermediate 4 dihydrochloride	ADC Payload Drug Intermediate	Cancer
Exatecan Intermediate 4 dihydrochloride (Compound 14f) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

Exatecan Intermediate 2 hydrochloride	ADC Payload Drug Intermediate	Cancer
Exatecan Intermediate 2 hydrochloride (Compound B) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

Exatecan Intermediate 4	ADC Payload Drug Intermediate	Cancer
Exatecan Intermediate 4 (Compound 14f) is an intermediate of Exatecan (DX-8951, HY-13631). Exatecan is an anticancer agent belonging to the class of camptothecin analogs. Exatecan interferes with the proliferation and division of tumor cells by interacting with DNA, thereby inhibiting tumor growth. Exatecan is primarily used for research of a variety of cancers including ovarian, lung and breast cancers .

Gαi2-IN-1	Others	Cancer
Gαi2-IN-1 (Compound 14) is a Gαi2 inhibitor. Gαi2-IN-1 significantly inhibits cancer cells migration induced by the chemotherapeutic drug, such as Vorinostat (HY-10221) and Docetaxel (HY-B0011). Gαi2-IN-1 can be used for cancers like prostate, breast and ovarian cancer research .

Annonacin	Potassium Channel Sodium Channel Na+/K+ ATPase Calcium Channel Apoptosis	Neurological Disease Cancer
Annonacin is an acetylgenin that is toxic by inhibiting the pathway of the mitochondrial complex. Annonacin increases tau phosphorylation in R406W ^+/+ mice. Annonacin acts as an inhibitor of the sodium/potassium and sarcoplasmic reticulum (SERCA) ATPase pumps. Annonacin has significant killing effect on ovarian cancer cell, cervical cancer cell, breast cancer cell, bladder cancer cell and skin cancer cell. Annonacin induces apoptosis through Bax and Caspase-3-related pathways .

CDK2-IN-44	CDK	Cancer
CDK2-IN-44 (Compound 46) is an inhibitor of cyclin-dependent kinase 2 (CDK2). CDK2-IN-44 can effectively inhibit the proliferation of cancer cells and exert its activity in inhibiting cancer cell growth by arresting the cell cycle, promoting Apoptosis, and inducing cellular senescence. CDK2-IN-44 holds promise for use in the research of ovarian cancer and breast cancer .

D-G23	RAD51	Cancer
D-G23 is a selective RAD52 inhibitor. D-G23 disrupts RAD52-mediated DNA repair pathways and suppresses the growth of BRCA1- and BRCA2-deficient cancer cells. D-G23 is promising for research of homologous recombination-related cancers, such as hereditary breast cancer and ovarian cancer caused by BRCA1/2 mutations .

Cat. No.	Product Name	Target	Research Area

HY-13673A

Goserelin acetate ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613); EP-100	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-P11018

(123B9)2-L2-PTX	Peptide-Drug Conjugates (PDCs) Ephrin Receptor	Cancer
(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .

Cat. No.	Product Name	Target	Research Area

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99101

Vobramitamab AEX-4089; MGC026 antibody	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P991723

Varsetatug CX-2051 antibody	Transmembrane Glycoprotein	Cancer
Varsetatug is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug has an antitumor activity. Varsetatug can be used for cancers such as breast, prostate and ovarian cancer research .

HY-P991608

CTM01 7F11C7	Mucin	Cancer
CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .

HY-P990873

Anti-BRCA1 Antibody (BR64)	DNA/RNA Synthesis	Cancer
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1 κ chimeric antibody, targeting to human BRCA1. Anti-BRCA1 Antibody (BR64) reacts with BRCA1 (Breast cancer susceptibility gene 1) involved in tumor suppression, transcription, genomic stability, DNA repair and recombination. Anti-BRCA1 Antibody (BR64) can be used for the detections of immunofluorescence, western blot, and immunoprecipitation in cancer, such as breast and ovarian cancer .

HY-P991292

AB-3A4	ADC Antibody	Cancer
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991372

Anti-TROP2 Antibody RN927C antibody	TROP2	Cancer
Anti-TROP2 Antibody (RN927C antibody) is a human monoclonal antibody (mAb) targeting TROP2. Anti-TROP2 Antibody has an inhibitory effect on multiple tumor cell lines in vitro. Anti-TROP2 Antibody has anti-tumor activity in mouse pancreatic PDX, ovarian PDX, lung LG0476 PDX, and triple-negative breast cancer (TNB) PDX models .

Cat. No.	Product Name	Chemical Structure

HY-16560S

Camptothecin-d5

Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-13673S2

Goserelin-d7 TFA
Goserelin-d₇ (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-13673S1

Goserelin-d7
Goserelin-d₇ (ICI 118630-d₇) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-13673S

Goserelin-d10
Goserelin-d₁₀ (ICI 118630-d₁₀) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-13632S

Exemestane-d2
Exemestane-d₂ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .

HY-13632S2

Exemestane-d3
Exemestane-d₃ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .

HY-13632S1

Exemestane-13C3
Exemestane- ¹³C₃ is the ¹³C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .

HY-13632S6

Exemestane-d4
Exemestane-d₄ (FCE 24304-d₄) is deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and *rat ovarian* aromatase*, respectively. Exemestane can be used for hormone-dependent breast* cancer research .

HY-13632S5

Exemestane-13C,d2
Exemestane- ¹³C,d₂ is ¹³C and deuterated labeled Exemestane (HY-13632). Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and *rat ovarian* aromatase*, respectively. Exemestane can be used for hormone-dependent breast* cancer research .

HY-109583S

4-Oxofenretinide-d4
4-Oxofenretinide-d₄ (4-Oxo-4-HPR-d₄) is deuterium labeled 4-Oxofenretinide. 4-Oxofenretinide (4-Oxo-4-HPR) is a metabolite of Fenretinide (HY-15373). 4-Oxofenretinide induces cell growth inhibition in ovarian, breast, and neuroblastoma tumor cell lines. 4-Oxofenretinide causes a marked accumulation of cells in G2-M. 4-Oxofenretinide induces cancer cell apoptosis through caspase-9 .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P86790

	BRCA2 Antibody (YA6483) BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and Ovarian cancer susceptibility gene early onset antibody; Breast and Ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2, DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and Ovarian cancer susceptibility gene early onset antibody; Breast and Ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; Breast Cancer 2 tumor suppressor antibody; Breast cancer susceptibility protein BRCA2 antibody; Breast cancer type 2 susceptibility protein antibody; BROVCA2 antibody; FACD antibody; FAD 1 antibody; FAD antibody; FAD1 antibody; FANCB antibody; FANCD 1 antibody; FANCD antibody; FANCD1 antibody; FANCD1 gene antibody; Fanconi anemia complementation group D1 antibody; Fanconi anemia group D1 protein antibody; GLM3 antibody; mutant BRCA2 antibody; OTTHUMP00000018803 antibody; OTTHUMP00000042401 antibody; PNCA2 antibody; XRCC11 antibody;	WB, FC	Human
	BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks